Trials / Completed
CompletedNCT03302806
Study to Assess Effect and Safety of High Dose of Biotin (Qizenday®) in Progressive Multiple Sclerosis
Observational Study to Assess Effect and Safety of High Dose of Biotin (Qizenday®) in Progressive Multiple Sclerosis
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 103 (actual)
- Sponsor
- Nantes University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this observational study is to collect efficacy and safety data in real life condition within the first year of treatment in patients with progressive multiple receiving a daily dose of biotine of 300 mg.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Non interventional Study |
Timeline
- Start date
- 2016-06-29
- Primary completion
- 2017-10-04
- Completion
- 2018-10-24
- First posted
- 2017-10-05
- Last updated
- 2021-09-21
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT03302806. Inclusion in this directory is not an endorsement.